Waldmeier P C, Maître L
Naunyn Schmiedebergs Arch Pharmacol. 1976 Aug;294(2):133-40. doi: 10.1007/BF00507845.
Behavioural and somatic responses to L-DOPA in rats are potentiated by short-term pretreatment with pargyline. It was therefore of interest to study the influence of the delay between pargyline pretreatment and L-DOPA-injection on the fate of the latter in rat brain. In rats treated with pargyline (50 mg/kg s.c.), the half-lives of recovery of striatal MAO activity and normal endogenous contents of homovanillic and 3,4-dihydroxyphenylacetic acids in striatum ranged from 9 to 14 days. The same treatment led to a marked increase (50-100-fold) in the accumulation of 3H-methoxytyramine in whole brain and, though less so, in 3H-dopamine formed from i.v. 3H-DOPA. Recovery from this effect of pargyline, however, was more rapid with a half-life of 15-19 h. Similar changes were observed when 3H-DOPA or 3H-dopamine was injected intracisternally, indicating that the phenomenon did not take place in the cerebral blood capillary walls, which are known to contain DOPA decarboxylase and MAO activities. The only labelled deaminated metabolite of dopamine in the brain after 3H-DOPA i.v. was 3H-homovanillic acid, which was strongly reduced 2 h after pargyline, but normalized after 24 h of pretreatment with the MAO inhibitor. When 3H-alpha-methyldopa instead of 3H-DOPA was injected, no increase in 3H-alpha-methyldopamine and its O-methylated derivative was produced by pargyline pretreatment. Moreover, in an experiment in which the animals were pretreated with pargyline at various times up to 21 days, a second injection of the MAO inhibitor 1.5 h before 3H-DOPA restored the increase in 3H-DA + 3H-MT observed with a single treatment with pargyline 1.5 h before the labelled amino acid. These results suggest that this short-lasting effect of the MAO inhibitor is related to the MAO inhibitory properties of the drug. The threshold dose of pargyline for producing the short-term effect was about 10 times higher than that for an overall MAO (DA deaminating) inhibition. However, it seems unlikely that this was due to near maximal inhibition of overall MAO activity, i.e. that it occurred only when MAO was inhibited by more than, say, 90%. The data reported suggest the existence of a small portion of an additional form of MAO with a rapid turnover and with a marked capacity to deaminate dopamine or methoxytyramine, and a greater resistance to inhibition by pargyline than cerebral MAO in general.
用优降宁进行短期预处理可增强大鼠对左旋多巴的行为和躯体反应。因此,研究优降宁预处理与左旋多巴注射之间的时间间隔对后者在大鼠脑中命运的影响很有意义。在用优降宁(50毫克/千克,皮下注射)处理的大鼠中,纹状体单胺氧化酶活性恢复的半衰期以及纹状体中高香草酸和3,4 - 二羟基苯乙酸的正常内源性含量的半衰期为9至14天。相同处理导致全脑中3H - 甲氧基酪胺的积累显著增加(50 - 100倍),静脉注射3H - 多巴形成的3H - 多巴胺的积累增加幅度较小。然而,优降宁这种作用的恢复更快,半衰期为15 - 19小时。当脑池内注射3H - 多巴或3H - 多巴胺时也观察到类似变化,这表明该现象并非发生在已知含有多巴脱羧酶和单胺氧化酶活性的脑毛细血管壁中。静脉注射3H - 多巴后,脑中多巴胺唯一标记的脱氨基代谢产物是3H - 高香草酸,优降宁处理2小时后其含量大幅降低,但用单胺氧化酶抑制剂预处理24小时后恢复正常。当注射3H - α - 甲基多巴而非3H - 多巴时,优降宁预处理不会使3H - α - 甲基多巴胺及其O - 甲基化衍生物增加。此外,在一项实验中,动物在长达21天的不同时间用优降宁预处理,在注射3H - 多巴前1.5小时第二次注射单胺氧化酶抑制剂可恢复在标记氨基酸前1.5小时单次用优降宁处理时观察到的3H - 多巴胺 + 3H - 甲氧基酪胺的增加。这些结果表明,单胺氧化酶抑制剂的这种短期作用与药物的单胺氧化酶抑制特性有关。产生短期效应的优降宁阈值剂量比总体单胺氧化酶(多巴胺脱氨基)抑制的阈值剂量高约10倍。然而,这似乎不太可能是由于总体单胺氧化酶活性接近最大抑制,即仅当单胺氧化酶被抑制超过90%左右时才会发生。所报道的数据表明存在一小部分额外形式的单胺氧化酶,其周转速度快,对多巴胺或甲氧基酪胺的脱氨基能力显著,并且比一般脑单胺氧化酶对优降宁的抑制具有更大的抗性。